Pozelimab is a medication being studied for its potential to help with geographic atrophy, a condition related to age-related macular degeneration. It is administered through an injection under the skin. The goal of using this medication is to see if it can slow down the growth of lesions in the eye by inhibiting a part of the immune system known as Complement Component 5 (C5).

Cemdisiran is another medication involved in the study, which is also being tested for its effects on geographic atrophy. Like Pozelimab, it is used to target the immune system, specifically aiming to reduce the activity of Complement Component 5 (C5). This medication is being tested both on its own and in combination with Pozelimab to determine its effectiveness in slowing down the progression of the disease.

Geographic Atrophy Secondary to Age-Related Macular Degeneration – This disease is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp vision. It is characterized by the gradual degeneration of retinal cells, leading to the formation of atrophic areas where the cells have died. Over time, these areas expand, causing a loss of central vision, which is crucial for activities like reading and recognizing faces. The progression of the disease is typically slow, but it can vary among individuals. It is a common form of advanced age-related macular degeneration, primarily affecting older adults. The condition does not usually cause complete blindness, as peripheral vision is often preserved.